GlobeNewsWire
23 Mar 2026, 20:16 UTC · 29w ago
Impact · against what's priced in
Context Therapeutics provides concrete timelines for Phase 1a data readouts for CTIM-76 and CT-95 in mid-to-late 2026, creating clear catalysts for the stock. The confirmation of a cash runway extending into mid-2027 reduces immediate financing risk.
No priced-in read yet
What the story claims
3 claims · scored −1 bearish … +1 bullish
Context Therapeutics expects to report Phase 1a interim data for CTIM-76 in June 2026 and for CT-95 in September 2026.
So whatClinical data readouts are the primary catalysts for biotech valuation, as they determine the viability of the drug pipeline.
More positive than 94% of claims this week
The company holds $66.0 million in cash and cash equivalents, providing a runway into mid-2027.
So whatA clear cash runway reduces the immediate risk of dilutive financing, though it remains a critical metric for clinical-stage firms.
Continue reading
5 related stories
The company established specific dates for Phase 1a interim data for CTIM-76 (June 2026) and CT-95 (September 2026), while confirming $66.0 million in cash to fund operations into mid-2027.
Read from the article alone
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More positive than 80% of claims this week
Context Therapeutics plans to dose the first patient in the CT-202 Phase 1 trial in the third quarter of 2026.
More positive than 56% of claims this week
Which stocks this story touches
More positive than 80% of ticker scores this week
The company reported progress in its clinical pipeline and maintains a cash runway extending into mid-2027.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Business Wire
1h ago
−91.5%
Price is moving against the score
$0.2556 vs $3.02 close before publication (Mar 23) · not market-adjusted
CNTX chart →
